Ongoing research into specific macrophage-targeted therapies, including cytokine inhibitors, and NLRP3 inflammasome inhibitors, holds the potential to improve outcomes for patients suffering from ALI. This evidence concerns the gene NLRP3 and acute respiratory distress syndrome.